Drug Name: Tofidence
Active Ingredient: tocilizumab-baviIndications: Tofidence is an interleukin-6 (IL-6) receptor antagonist that targets specific inflammatory proteins to suppress the immune system. Tofidence is approved for rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis ages 2 and older, and systemic juvenile idiopathic arthritis ages 2 and older.
Approval Date: September 29, 2023
Company: Biogen Inc.More: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-biosimilar-actemra-treat-adult-and-pediatric-arthritis